Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|August 14, 2020
Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trialsDavid B Clemow, Simin K Baygani, Paula M Hauck, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 28, 2015
Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylating E3 ligaseChristopher N Batuello, Paula M Hauck, Jaimie M Gendron, et al.
Oncotarget|December 22, 2017
The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2)Paula M Hauck, Eric R Wolf, David J Olivos, et al.
Clinical Therapeutics|August 9, 2021
Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized StudiesVincent T Martin, Zubair Ahmed, Helen M Hochstetler, et al.
CNS Drugs|July 2, 2022
The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical TrialsErin G Doty, Paula M Hauck, John H Krege, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 19, 2023
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trialsCynthia D Evans, JonDavid Sparks, Scott W Andersen, et al.
Plos One|September 17, 2013
Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymesJason A Lehman, Paula M Hauck, Jaimie M Gendron, et al.
The Journal of Headache and Pain|August 29, 2021
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTANRichard B Lipton, Simin K Baygani, Stewart J Tepper, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|March 18, 2008
Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic responseSanthosh Girirajan, Paula M Hauck, Stephen Williams, et al.
Molecular Cancer Research : MCR|August 9, 2017
Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of FunctionPaula M Hauck, Eric R Wolf, David J Olivos, et al.
Pageof 2